American Health Packaging

Complete recall history across all FDA and CPSC categories — 59 total recalls

American Health Packaging appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.

Drug Recalls (59)

FDA drug safety enforcement actions by American Health Packaging. Showing most recent 50.

Date Product Reason Class
May 3, 2022 Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals), 100 mg, 100 Capsule... Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to di... Class III
Apr 12, 2022 Cyanocobalamin Injection, USP, 1000 mcg per mL, For Intramuscular or Subcutan... Subpotent Drug: Out of specification for assay. Class III
Feb 22, 2022 Oxycodone Hydrochloride Oral Solution, USP (C-II), 5 mg/5 mL, Delivers 5 mL p... Impurity failure at 0-time of the repackaged lot. Class II
Dec 20, 2021 Metoprolol Succinate Extended-Release Tablets, USP 50 mg, 500-count bottle, R... Failed Dissolution Specifications Class II
Sep 17, 2021 GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each ... Failed Dissolution Specifications: results were above specification. Class II
Sep 15, 2021 Valproic Acid Oral Solution, USP, 500 mg/10 mL, 100 10 mL unit dose cups per ... CGMP Deviations: Potential concern with products manufactured using liquid su... Class II
May 12, 2021 Sirolimus Tablets 1 mg, 30 Tablets (5 blister cards x 6 unit doses), Rx only,... Failed Impurities/Degradation Specifications Class III
Jan 7, 2021 Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100 per cart... Failed Dissolution Specifications Class II
Jun 10, 2020 Nabumetone Tablets, USP, 500 mg, 100 Tablets per carton (10 tablets x 10 blis... Labeling Not Elsewhere Classified: The statement Pharmacist: Dispense with t... Class III
May 19, 2020 Doxycycline Hyclate Tablets, USP, 100 mg, 30 Tablets per carton (3 x 10), Rx ... Failed dissolution specification - dissolution results of 59% (spec. NLT 85%)... Class II
Feb 7, 2020 Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister ca... GMP Deviations: Product bottle may be absent of desiccant. Class II
Feb 7, 2020 Desmopressin Acetate Tablets, 0.1 mg, 30 tablets (3 x 10 unit dose blister ca... GMP Deviations: Product bottle may be absent of desiccant. Class II
Dec 4, 2019 Raloxifene Hydrochloride Tablets, USP, 60 mg, 30 Tablets (3 x 10 blister card... Failed Dissolution Specifications: Low out of specification results obtained ... Class II
Nov 20, 2019 Ranitidine Tablets, USP, 150 mg, 100 Tablets (10 tablets x 10 blister card), ... CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels... Class II
Nov 1, 2019 Ranitidine Syrup (Ranitidine Oral Solution USP), 15 mg/mL, 150 mg/10 mL per c... CGMP Deviations: Presence of NDMA impurity detected in product. Class II
Aug 27, 2019 Lamivudine Tablets, USP, 150 mg, 30 (3x10) count Unit Dose Blisters Carton, N... Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms ... Class III
Aug 9, 2019 Carbamazepine, Extended-Release Tablets, USP, 400 mg, 30 Tablets (3 blister c... Failed Dissolution Specifications Class II
May 13, 2019 Pramipexole Dihydrochloride Tablets, 0.25 mg, 100 Tablets (10 x 10), Rx Only,... GMP Deviations; possible cross contamination of product due to cleaning proce... Class II
May 13, 2019 Pramipexole Dihydrochloride Tablets, 0.5 mg, 30 Tablets (6 tablets per bliste... GMP Deviations; possible cross contamination of product due to cleaning proce... Class II
May 13, 2019 Pramipexole Dihydrochloride Tablets, 1.0 mg, 30 Tablets (6 tablets per bliste... GMP Deviations; possible cross contamination of product due to cleaning proce... Class II
May 13, 2019 Pramipexole Dihydrochloride Tablets, 0.125 mg, 30 Tablets (6 tablets per blis... GMP Deviations; possible cross contamination of product due to cleaning proce... Class II
May 9, 2019 Anastrozole Tablets, USP, 1mg, 30-count unit dose blisters per carton, Rx Onl... GMP Deviations: Potential cross contamination due to cleaning procedure failure. Class II
May 9, 2019 Anastrozole Tablets, USP, 1 mg, a) 30-count (NDC 68001-155-04) and 1000-count... GMP Deviations: Potential cross contamination due to cleaning procedure failure. Class II
Apr 8, 2019 GlipiZIDE Extended-release Tablets, 2.5 mg, 30 Tablets (3 x 10), Rx Only, Pac... Failed Dissolution Specifications: dissolution failure at time zero of the re... Class II
Mar 6, 2019 Valsartan Tablets USP 160 mg, 100 Tablets (10 x 10) per Unit Dose Blisters, ... CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impur... Class II
Mar 1, 2019 Aspirin and Extended-release Dipyridamole Capsules, 25 mg/200 mg, 20 capsules... Failed Impurities/Degradation Specifications; out of specification result for... Class II
Feb 19, 2019 Lovastatin Tablets USP, 40 mg, packaged in a) 100-count bottles (NDC 68001-31... CGMP Deviations: Finished product made with lovastatin drug substance that wa... Class III
Nov 9, 2018 Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100-count Un... Cross contamination with other products: This sub-recall is being initiated i... Class III
Aug 1, 2018 Doxycycline Hyclate Tablets, USP, 100 mg, 30 Tablets per carton (3 x 10 Unit ... Failed Dissolution Specifications: Out of specification result for the dissol... Class II
Jun 25, 2018 Enalapril Maleate Tablets USP, 5 mg, 100 Tablets (10X10) blister cards, 12 ca... Failed Impurities/Degradation Specification; out-of-specification results for... Class III
Jan 19, 2018 Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [N... CGMP Deviations: lot made with active pharmaceutical ingredient that did not ... Class II
Jun 26, 2015 Desmopressin Acetate Tablets, 0.1 mg Tablets, Rx Only, Packed in 30 Tablet (3... Tablets/Capsules Imprinted with Wrong ID: Some tablets incorrectly imprinted ... Class III
Jun 1, 2015 Azithromycin tablets, USP 600mg, packaged in 10-count blisters (NDC 68084-464... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Lisinopril tablets, USP 10mg packaged in 10-count blisters (NDC 68084-061-11)... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Amlodipine besylate tablets, USP 5mg, packaged in 10-count blisters (NDC 6808... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Lisinopril tablets, USP 20mg packaged in 10-count blisters (NDC 68084-062-11)... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Famotidine tablets, USP 20mg, packaged in 10-count blisters (NDC 68084-172-11... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Amlodipine besylate tablets, USP 10 mg, packaged in 10-count blisters (NDC 68... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Azithromycin tablets, USP 250mg, packaged in 10-count blisters (NDC 68084-278... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Lisinopril tablets, USP 40mg packaged in 10-count blisters (NDC 68084-064-11)... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Lisinopril tablets, USP 5mg packaged in 10-count blisters (NDC 68084-060-11);... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Azithromycin tablets, USP 500mg, packaged in 10-count blisters (NDC 68084-279... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Zonisamide capsules, USP 100mg packaged in 10-count blisters (NDC 68084-008-1... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Amlodipine besylate tablets, USP 2.5mg, packaged in 10-count blisters (NDC 68... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Jun 1, 2015 Clarithromycin tablets, USP 500mg, packaged in 10-count blisters (NDC 68084-4... CGMP Deviations: Firm did not adequately investigate customer complaints. Class II
Mar 2, 2015 Lamivudine and Zidovudine Tablets USP 150mg/300mg 30 Unit Dose Blisters, Rx O... Failed dissolution specifications Class II
Jan 6, 2015 Benzonatate Capsules, USP, 100 mg, 100 count (10X10), Rx only, Packaged and D... Failed Tablet/Capsule Specifications; recall initiated by manufacturer due to... Class II
Nov 19, 2014 Mercaptopurine Tablets, USP, 50 mg, 30 Tablets (3 x 10) unit dose blisters pe... Failed USP Dissolution Test Requirements: This sub-recall is in response to P... Class II
Oct 10, 2014 MethylPREDNISolone Tablets, USP, 4 mg, 100 unit dose blisters, Packaged and D... Subpotent; 6 month stability time point Class III
Jul 1, 2014 Oxcarbazepine Tablets, 300 mg, 100 tablets per carton (10 x 10), Rx Only, Pac... Labeling: Label Mix-Up: Some cartons of AHP Ibuprofen Tablets, USP, 600mg, lo... Class I

View all 59 drug recalls →

Frequently Asked Questions

A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.

Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.

The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.

Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.

Explore More Recalls

Search recalls by category, state, reason, or firm across all our databases.